Current treatments for Parkinson’s disease (PD) effectively treat only some of the symptoms of the disease, but they do not slow or stop the progression of the underlying disorder. So, while neurologists may be skilled at treating many of the motor symptoms of PD, they cannot prevent patients from getting worse over time. What we need is a way to slow or halt the degeneration of the nerve cells that die over time in PD. By studying the molecular mechanisms that kill neurons in PD, and by testing new therapeutic approaches in the lab, it is hoped that we can develop new neuroprotective treatments. As opposed to current symptomatic therapies, neuroprotective treatments are designed to slow or stop disease progression and are often referred to as “disease-modifying” therapies.

Funds awarded by the Blechman Foundation will be used for pilot projects aimed at developing new neuroprotective strategies. It is hoped that experimental, therapeutic approaches that protect neurons in models of PD can ultimately be translated into new treatments to slow or halt the disease progression in people living with PD. If successful and effective, neuroprotective therapies should result in an improved quality of life for a much longer period. The specific project(s) to be funded will be determined by an Advisory Committee at the Pittsburgh Institute for Neurodegenerative Diseases (PIND). The Foundation is pleased to support these efforts through the generous donations of its contributors.

If you have questions or are interested in learning more about our grant process, please email contact_us@blechmanfoundation.org.